Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Full-Body PET scanner promises faster scans, less radiation

NCT ID NCT07263815

Knowledge-focused Sponsor: Peter MacCallum Cancer Centre, Australia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess whether image quality is as good or better than current scanners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET/CT scanner (GE Omni Total Body 128cms)
What this could lead to
If successful, this scanner could allow faster, lower-radiation PET scans without losing image quality, improving patient comfort and safety.
What could go wrong
This is a small, early-stage imaging study (25 participants) focused on feasibility, not treatment. The new scanner may not prove superior in routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult, who is at least 18 years of age 2. Referred for a clinically indicated PET/CT scan with radiotracers F-18 FDG, F-18 DCFPyL, Ga-68 PSMA, Ga-68 DOTATATE or I-124 3. Able and willing to provide informed consent for participation in this study Exclusion Criteria: 1\) Known to be pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer disease neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.